INTRODUCTION

I
n the last fifteen years, the increase of patients with prostatic cancer (CaP) was reported 1 . The incidence rise was mostly the result of the utilization of test which was discovered at the end of 1980s. Determination of serum prostatic specific antigen (PSA) level may indicate the presence of clinically undetectable cancer of prostate 1, 4, 9 .
In the majority of countries, prostatic cancer is one of the most frequently diagnosed cancers in male population, representing the leading cause of cancer-related mortality 2, 4 . Screening programs are designed for detection of prostatic cancer in early stage when cure is possible by radical treatment 3, 15 . A number of reference articles in this field has evaluated the possibility of detection of prostatic cancer by radioimmunoassay (RAI) 10, 11, 20 . So far, PSA has been the best tumor marker of prostatic adenocarcinoma detection, although it is not capable of making a difference between benign prostatic hyperplasia (BPH) and CaP. The possibilities of PSA test for screening may be evaluated by determination of its sensitivity, specificity and positive predictive value.
MATERIAL AND METHODS
The objective of our study was to examine the possibilities of enzyme PSA immunoassay for differentiation of localized CaP from BPH. PSA test was compared with digital rectal examination (DRE) and transrectal ultrasonography. An attempt has been made to increase the predictive value by introduction of PSA derivative test, i.e. PSA density (PSAD) and age reference values of PSA.
Prospective study included 2000 patients over 50 years of age. Before rectal examination, their blood was drawn for determination of serum PSA level. If PSA value was over 4.0ng/ml, transrectal ultrasound-guided, targeted and randomized sextant biopsy was performed. The patients with suspected findings obtained by digital rectal examination underwent biopsy regardless of the PSA value.
Biopsy was done in 256 patients with PSA value over 4.0ng/ml. Benign prostatic hyperplasia was found in 158 patients, while CaP was verified in 98 cases who were subsequently treated by standard therapeutical protocol. In patients with PSA of 4-10 ng/ml, prostatic cancer was verified in 28.8% of cases, and in the group PSA of 10-20 ng/ml, it was found in 68.4% of the time.
The comparison of mean PSA values of BPH and CaP patients found highly significant difference in the PSA group of 4-20 g/ml (t=08.7, DF=183, p<0.01). There was also highly significant difference between mean PSA values of CaP and BPH patients in PSA group of 4-10 ng/ml (t=6.5, DF=169, p<0.01).
Mean PSAD value in patients with PSA level lower than 4.0 ng/ml revealed no significant difference in relation to mean PSAD values obtained in patients with negative bioptic results (X 2 =123.4, p>0.01). Highly significant difference was found by monitoring PSA density (PSAD) of patients with prostatic cancer and benign prostatic hyperplasia for PSA of 10-20 ng/ml (t=5.3, DF=157, p<0.01), as well as for PSA of 4-10 ng/ml (t=4.5, DF=149, p<0.01). (Table 2,3) .
If the reference border-line value of PSAD is 0.10, meaning that density over 0.10 designates the cancer, test sensitivity is 0.69, specificity is 0.97, positive predictive value (PPV) is 0.62, and negative predictive value (NPV) is 0.98.
Highly significant difference was found between reference PSA values and age-specific groups (E=0.256, DF=156, p<0.01) as well as between PSAD values and age-specific groups (r=0.192, DF=42, p<0.01). (Table  4 ,5)
DISCUSSION
The sensitivity of tumor marker indicates its possibility to detect the disease in patients who are truly ill 6 . It is not possible to compute precisely the test sensitivity for prostatic cancer, because radical prostatectomy is not carried out unless there is distinct evidence of cancer. Although precise determination of marker sensitivity is impossible, the test in use must have capacity to detect high proportion of cases in the group of patients who are really ill 5 . ROC analysis has found that PSA, among current diagnostic tests for detection of prostatic cancers, has the highest sensitivity with maximal specificity when 4.0 ng/ml is taken as the reference value. On the other hand, in the last few years, it became quite clear that border-line value of 4.0 ng/ml cannot be considered the reference one. For PSA values of 2.5 to 4.0 ng/ml, detection rate of CaP is up to 20% 21 . Test sensitivity rises with the increase of border-line PSA value and reaches the maximum for PSA of 15 ng/ml when specificity falls to 0.71. Values between 4 ng/ml and 15 ng/ml are problematic because, between these two levels, the test is not able to distinguish cancer from benign prostatic hyperplasia. For this reason, additional tests are introduced such as PSA density and age specific values of PSA. On the basis of our knowledge on natural course of prostatic cancer and particularly on its low rate of progressiveness, it is not necessary for PSA test to be extremely sensitive as a method for screening 8, 12 . On the contrary, it is important that this test is highly specific in order to evade a large number of false positive results which require further diagnostic evaluation what leads to unnecessary expenses and, more important, discomfort of patients.
In study of Labrie et al 10 with 1002 subjects, sensitivity of PSA test was 0.72, specificity 0.91, positive predictive value 0.33, and negative predictive value 0.98, what was comparable with results of enzyme test in our study. According to predictive values, it may be noted that digital rectal examination and serum PSA level are the most important tests for early detection of prostatic cancer. Although early detection of prostatic cancer may be done by transrectal ultrasonography, this method is not suitable for screening because of a large number of false positive results and low positive predictive value.
The comparison of BPH patients and patients with malignancy diagnosed by biopsy found highly significant difference of mean values of PSAD. Such finding was expected since it is well known that a gram of tissue of pro- 15, 16 . For clinical employment, it is crucial that there is significant difference between mean PSAD values of the controls and patients with cancer having PSA of 4-10 ng/ml. Mean PSAD values of patients with negative biopsy results and patients with verified tumor in 4-10 ng/ml group did not differ significantly. The obtained values of PSA density were comparable with results of Seaman and assoc. 7 The significance of study lies in the fact that it may determine the reference values of enzyme PSA immunoassay. The actual border-line PSAD value of 0.15 17 is not ideal since there is "grey zone" ranging from 0.10-0.20. With a wish to reduce the number of false positive results, we tested the border-line value for PSAD 0.10, whose sensitivity of 0.69, specificity of 0.97, PPV of 0.62 and NPV of 0.98 was inferior in relation to PSA test possibilities if value of 4ng/ml were considered the referential. Then, we tested whether the possibility of PSA test for differentiation of BPH and cancer could be improved by PSAD age-specific ranges.
In their prospective study, Oesterling and assoc. 19, 21 showed that median of serum PSA increased with each age decade. Using 95 percentil, they found that the upper normal serum PSA concentration in 45-year old man was 2.5ng/ml, in distinction from 75-year old man in whom the limit was 6.5ng/ml, what was all verified by Tandem-R assay (radioimmunoassay). In our study, reference levels by age-specific groups exhibited highly significant difference (p<0.01). The results reported by Oesterling and assoc. are slightly higher in comparison with ours and almost identical with the results obtained by Dalkin et al 20 , where the upper border-line value in 70-74-yea old patients was 6.6ng/ml. Radioimmunoassays were used in both studies, because the role of enzyme immunoassay was not confirmed. Since the utilization of enzyme immunoassay has become everyday clinical practice, the significance of this study reflects in standardization of agespecific values of PSA, since they differ from earlier widely used RIA method.
The elevation of serum PSA, besides the volume of the prostate, is affected by the age of the subjects 22 . Determination of reference PSAD values for age-specific groups includes both factors with an attempt to increase the predictive value of test 23 . The results of our study related to these values are somewhat higher than those obtained by authors who tested RIA method, but, in any case, they are comparable. This study contributes to standardization of enzyme immunoassay.
CONCLUSION
The results of EIA method are comparable with RIA test results. Diagnostic algorithm for detection of prostatic cancer should be corrected by density values according to age-specific groups, in order to reduce the number of false positive results in PSAD "grey zone" (0.10-0.20). REZIME UVOD: Mogu}nosti PSA (prostata specifi~ni antigen) testa u skriningu karcinoma prostate mogu se evaluirati odredjivanjem njegove senzitivnosti, specifi~nosti i pozitivne prediktivne vrednosti. Ve}ina referentnih radova iz ove oblasti evaluirala je mogu}nost detekcije karcinoma prostate radioimunoesejom (RIA).
MATERIJAL I METODE: Prospektivnom studijom je obuhva}eno 2000 pacijenata mu{kog pola starosti preko 50 godina. Cilj studije je bio da se ispita mogu}nost enzimskog PSA testa u diferencijaciji benigne hiperplazije prostate (BPH) i lokalizovanog prostati~nog karcinoma (PC). Mogu}nost enzimskog PSA eseja u detekciji prostati~nog karcinoma komparirana je sa RIA metodom, digitalnim rektalnim pregledom i nalazom ehotomografije. Uticaj gustine PSA testa (PSAD) i starosno referentnih vrednosti u razlikovanju PC od BPH je takodje ispitano.
DISKUSIJA: Rezlutati enzimskog imunoesej testa (EIA) su komparabilni sa radioimunoesej rezultatima (RIA). Dijagnosti~ki algoritam za detekciju karcinoma prostate treba korigovati sa vrednostima PSA za gustinu prema starosno specifi~nim grupama (49 godina -0,09 ng/ml/cm 
